Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saxagliptin with Glyburide in Type 2 Diabetes
NCT00313313Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2006
- Primary completion
- Sep 2007
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of saxagliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by AstraZeneca. Primary endpoint: Change From Baseline in Hemoglobin A1c at 24 weeks. Started Apr 2006; status: completed.
02
Drugs
saxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00313313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00313313.